[Assessment of risk of cerebral infarction and benefit of anticoagulant therapy in a patient with atrial fibrillation]. / Eteisvärinäpotilaan aivoinfarktin vaaran ja antikoagulaatiohoidon hyödyn arviointi.
Duodecim
; 130(1): 47-53, 2014.
Article
em Fi
| MEDLINE
| ID: mdl-24547624
ABSTRACT
The risk of cerebral infarction in patients with atrial fibrillation varies from 0.5% to more than 10% per year. Anticoagulant therapy is recommended today more than before, but to a low-risk patient anticoagulation may cause harm that is larger than the expected benefit. Assessment of the risk of cerebral infarction is therefore essential. Use of the CHA2DS2-VASc risk index enables reliable identification of low-risk patients who do not benefit from anticoagulation. Individual treatment decisions may even be necessary.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Fibrilação Atrial
/
Infarto Cerebral
/
Anticoagulantes
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
Fi
Ano de publicação:
2014
Tipo de documento:
Article